
TNDM — Tandem Diabetes Care Inc
NASDAQ · Healthcare · Medical Devices
$21.50
+$0.22 (+1.03%)
Tandem Diabetes Care Inc (TNDM) is a medical devices company listed on NASDAQ. It is led by John F. Sheridan, based in 12400 High Bluff Drive, San Diego, CA, United States, 92130, with about 2,500 employees. Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest reported TNDM revenue for 2025-09-30 was $249.3M. Net income was -$204.1M. Revenue was up 3.6% from 2025-06-30 to 2025-09-30. TNDM currently screens at market cap $1.06B.
Use this TNDM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TNDM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TNDM SEC filings page. Lician reads the product cache first so this HTML stays unique to Tandem Diabetes Care Inc even when a live quote feed is slow.
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
TNDM Key Statistics
Market Cap
$1.06B
Volume
1.12M
Previous Close
$21.58
Day Range
$21.02 – $21.59
P/B Ratio
7.97
EPS
$0.01
Revenue
$282.65M
Net Income
-$96.03M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+43.6%
Profit Margin
-34.0%
Employees
2,500
TNDM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $282.65M | $196.80M | $220.50M | $210.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$96.03M | -$222.61M | -$94.59M | $15.57M |
| EPS (Diluted) | $0.01 | -$0.46 | -$0.25 | $0.16 |
Total Assets
$967.66M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$69.23M
Operating Cash Flow
$24.23M
Free Cash Flow
$0.00
Tandem Diabetes Care Inc Company Information
- President, CEO & Director
- John F. Sheridan
- Headquarters
- 12400 High Bluff Drive, San Diego, CA, United States, 92130
- Website
- www.tandemdiabetes.com
- Phone
- 858 366 6900
- IPO / Founded
- 2013-11-14
- Sector
- Healthcare
- Industry
- Medical Devices